In patients with frequent severe hypoglycaemic events, allogeneic pancreatic islet transplantation results in better glycaemic control than insulin therapy alone, enhances quality of life, and reduces ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

A combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet leads to higher rates of type 2 diabetes ...

as well as kidney issues. On the flip side, recent studies show that GLP-1 medications may decrease a person’s risk for cardiovascular disease and dementia. Now, a new study recently published ...

However, they also found that GLP-1 drugs may lead to gastrointestinal, kidney, and pancreas ... obesity as a long-term chronic disease, like hypertension or diabetes. With that change, these ...

The researchers recruited 12,821 patients with type 2 diabetes who had elevated systolic blood pressure and were considered at increased risk of cardiovascular disease. The patients' average age ...

CKD GFR <60 mL/min per 1·7m 2 for ≥3 months. CKD staging: GFR categories. Kidney damage for ≥3 months. ACR categories. ACR=albumin-to-creatinine ratio. AKD=acute kidney disease. AKI=acute kidney ...

today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). “OCU200 has the potential to change the treatment landscape for DME ...

The phase 1 trial ... for DME, diabetic retinopathy (DR), and wet age-related macular degeneration (wet AMD) with its unique mechanism of action, binding the active component—tumstatin—to integrin ...